Progression-free survival and response rate with EGFR tyrosine kinase inhibitor treatment according to EGFR mutation subtype in advanced lung adenocarcinoma

被引：0
|
作者：
Chai, C. S. [1 ]
Liam, C. K. [2 ]
Pang, Y. K. [2 ]
Kow, K. S. [2 ]
Wong, C. K. [2 ]
Poh, M. E. [2 ]
Tan, J. L. [2 ]
机构：
[1] Univ Malaysia Sarawak, Fac Med & Hlth Sci, Dept Med, Kota Samarahan, Malaysia
[2] Univ Malaya, Fac Med, Dept Med, Kuala Lumpur, Malaysia
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
470P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] SEVERAL RECEPTOR TYROSINE KINASE IS ACTIVATED BUT ORCHESTRATED BY EGFR IN EGFR-TKI ACQUIRED RESISTANT LUNG ADENOCARCINOMA CELLS WITH EGFR MUTATION
    Suda, Kenichi
    Mizuuchi, Hiroshi
    Sato, Katsuaki
    Takemoto, Toshiki
    Iwasaki, Takuya
    Minami, Kenji
    Yatabe, Yasushi
    Mitsudomi, Tetsuya
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S771 - S772
  • [42] A case with small-cell transformation after treatment with EGFR tyrosine kinase inhibitor for lung adenocarcinoma
    Osoegawa, Atsushi
    Hashimoto, Takafumi
    Yohei, Takumi
    Miyuki, Abe
    Shuji, Suehiro
    Michiyo, Miyawaki
    Kenji, Sugio
    ANNALS OF ONCOLOGY, 2015, 26 : 138 - 139
  • [43] Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification of lung adenocarcinoma
    Chen, Zhen
    Liu, Xiaoyan
    Zhao, Jing
    Yang, Hanjin
    Teng, Xiaodong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (11): : 8039 - 8045
  • [44] Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
    Yu, Helena A.
    Sima, Camelia S.
    Huang, James
    Solomon, Stephen B.
    Rimner, Andreas
    Paik, Paul
    Pietanza, M. Catherine
    Azzoli, Christopher G.
    Rizvi, Naiyer A.
    Krug, Lee M.
    Miller, Vincent A.
    Kris, Mark G.
    Riely, Gregory J.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : 346 - 351
  • [45] Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
    Brindel, Aurelien
    Althakfi, Wajd
    Barritault, Marc
    Watkin, Emmanuel
    Maury, Jean-Michel
    Bringuier, Pierre-Paul
    Girard, Nicolas
    Brevet, Marie
    JOURNAL OF THORACIC DISEASE, 2020, 12 (09) : 4643 - +
  • [46] Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma
    Taus, Alvaro
    Camacho, Laura
    Rocha, Pedro
    Hardy-Werbin, Max
    Pijuan, Lara
    Piquer, Gabriel
    Lopez, Eva
    Dalmases, Alba
    Longaron, Raquel
    Clave, Sergi
    Salido, Marta
    Albanell, Joan
    Bellosillo, Beatriz
    Arriola, Edurne
    CLINICAL LUNG CANCER, 2018, 19 (05) : 387 - +
  • [47] Presence of pulmonary tuberculosis impair survival in advanced EGFR mutation lung adenocarcinoma patients receiving epidermal growth factor receptor-tyrosine kinase inhibitor.
    Xie, Yalin
    Zhou, Wei
    Lei, An
    Huang, Zhan
    Li Weiwei
    Zhu, Changbin
    Zhu, Guanshan
    Cen, Wenchang
    CANCER RESEARCH, 2021, 81 (13)
  • [48] Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
    Wang, Wenxian
    Jiang, Xiaowen
    Song, Zhengbo
    Zhang, Yiping
    ONCOTARGETS AND THERAPY, 2016, 9 : 211 - 214
  • [49] The use of gefitinib and erlotinib in locally advanced and metastatic EGFR mutant lung cancer - assessment of progression free survival according to mutation type
    Atkinson, C. E. L.
    Owczarczyk, K.
    Dickson, J.
    Maddox, A. J.
    LUNG CANCER, 2015, 87 : S29 - S30
  • [50] EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
    Yang, Jiyoul
    Lee, Ok-Jun
    Son, Seung-Myoung
    Woo, Chang Gok
    Jeong, Yusook
    Yang, Yaewon
    Kwon, Jihyun
    Lee, Ki Hyeong
    Han, Hye Sook
    CANCER RESEARCH AND TREATMENT, 2018, 50 (03): : 908 - 916
12345